UCSF Helen Diller Family Comprehensive Cancer Center
Protocol Summary

[ Back to Protocol Listing ]

[ Print this page ]

Protocol No.124511Principal InvestigatorKelley, Katie
PhaseII (Cancer Control)
Age GroupAdultScopeNational
Secondary Protocol No.Temsor
TitlePhase II Trial of the Combination of Temsirolimus and Sorafenib in Advanced Hepatocellular Carcinoma
ObjectiveTo determine the median time to progression (TTP) in patients with advanced HCC treated with combination of temsirolimus plus sorafenib
Key EligibilityAge: 18-85 *Patients must have histologically diagnosed AJCC stage II, III, or IV HCC not eligible for curative resection, transplantation, or ablative therapies
Applicable Disease SitesLiver
Therapies InvolvedChemotherapy multiple agents systemic
Drugs InvolvedCCI-779 (Temsirolimus)
Nexavar (Sorafenib)
Sorafenib
Temsirolimus
Torisel (Temsirolimus)
StatusOpen
Participating InstitutionsMt. Zion : Ryan Mcwhirter
Robert H. Lurie Comprehensive Cancer Center
Eligibility Document124511_CTGovEligibility_NCT01687673.docx
Other Attachments124511 Lay Summary
ContactRyan Mcwhirter Phone:415-353-7792
Pager:
Email:McWhirterR@cc.ucsf.edu